Somatic variations are frequent and important drivers in cancers. Amino acid substitutions can yield neoantigens that are detected by the immune system. Neoantigens can lead to immune response and tumor rejection. Although neoantigen load and occurrence have been widely studied, a detailed pan-cancer analysis of the occurrence and characterization of neoepitopes is missing. We investigated the proteome-wide amino acid substitutions in 8-, 9-, 10-, and 11-mer peptides in 30 cancer types with the NetMHC 4.0 software. 11,316,078 (0.24%) of the predicted 8-, 9-, 10-, and 11-mer peptides were highly likely neoepitope candidates and were derived from 95.44% of human proteins. Binding affinity to MHC molecules is just one of the many epitope featu...
Tumor-infiltrating lymphocytes (TIL) are considered enriched for T cells recognizing shared tumor an...
Neoepitopes are the only truly tumor-specific antigens. Although potential neoepitopes can be readil...
Background: Tumor-specific mutations form novel immunogenic peptides called neoantigens. Neoantigens...
Abstract Somatic variations are frequent and important drivers in cancers. Amino acid substitutions ...
Abstract Background Tumor neoantigens are drivers of cancer immunotherapy response; however, current...
Personalization of cancer immunotherapies such as therapeutic vaccines and adoptive T-cell therapy m...
abstract: Cells become cancerous due to changes in their genetic makeup. In cancers, an altered amin...
Personalization of cancer immunotherapies such as therapeutic vaccines and adoptive T-cell therapy m...
Neoantigens are novel peptide sequences resulting from sources such as somatic mutations in tumors. ...
Tumor-specific antigens can activate T cell-based antitumor immune responses and are ideal targets f...
<p>Personalization of cancer immunotherapies such as therapeutic vaccines and adoptive T-cell therap...
In prior studies, we delineated the landscape of neoantigens arising from nonsynonymous point mutati...
Somatic mutations in cancer can result in neoantigens against which patients can be vaccinated. The ...
Genetic mutations lead to the production of mutated proteins from which peptides are presented to T ...
Neoepitopes are the only truly tumor-specific antigens. Although potential neoepitopes can be readil...
Tumor-infiltrating lymphocytes (TIL) are considered enriched for T cells recognizing shared tumor an...
Neoepitopes are the only truly tumor-specific antigens. Although potential neoepitopes can be readil...
Background: Tumor-specific mutations form novel immunogenic peptides called neoantigens. Neoantigens...
Abstract Somatic variations are frequent and important drivers in cancers. Amino acid substitutions ...
Abstract Background Tumor neoantigens are drivers of cancer immunotherapy response; however, current...
Personalization of cancer immunotherapies such as therapeutic vaccines and adoptive T-cell therapy m...
abstract: Cells become cancerous due to changes in their genetic makeup. In cancers, an altered amin...
Personalization of cancer immunotherapies such as therapeutic vaccines and adoptive T-cell therapy m...
Neoantigens are novel peptide sequences resulting from sources such as somatic mutations in tumors. ...
Tumor-specific antigens can activate T cell-based antitumor immune responses and are ideal targets f...
<p>Personalization of cancer immunotherapies such as therapeutic vaccines and adoptive T-cell therap...
In prior studies, we delineated the landscape of neoantigens arising from nonsynonymous point mutati...
Somatic mutations in cancer can result in neoantigens against which patients can be vaccinated. The ...
Genetic mutations lead to the production of mutated proteins from which peptides are presented to T ...
Neoepitopes are the only truly tumor-specific antigens. Although potential neoepitopes can be readil...
Tumor-infiltrating lymphocytes (TIL) are considered enriched for T cells recognizing shared tumor an...
Neoepitopes are the only truly tumor-specific antigens. Although potential neoepitopes can be readil...
Background: Tumor-specific mutations form novel immunogenic peptides called neoantigens. Neoantigens...